Drugs / IPG11406
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06255834 | Feb → Dec 2024 | inflammatory bowel disease | Nanjing Immunophage Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06717815 | Feb 2025 → Apr 2026 overdue | lupus nephritis | Nanjing Immunophage Biotech Co., Ltd | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07535489 | Jul 2026 → Dec 2028 expected | ulcerative colitis | Nanjing Immunophage Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPG11406 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07535489 ↗ |
| Action | Inhibit | “An antagonist of the GPR183” NCT06255834 ↗ |
| Route | Oral | “orally administered” NCT06255834 ↗ |
| Target | GPR183 | “IPG11406 Activity: An antagonist of the GPR183” NCT06255834 ↗ |